Measurable Residual Disease for AML by Flow Cytometry (Pilot - Not Accredited)
ACCREDITATION STATUS:
Pilot - not accredited
This programme is operated by UK NEQAS Leucocyte Immunophenotyping. The centre provides flow cytometry and molecular haematology based programmes. For further information on the operation of the programme or details on current accreditation status please contact UK NEQAS Leucocyte Immunophenotyping directly.Email: admin@ukneqasli.co.uk
Telephone: +44 (0) 114 267 3600
CLINICAL APPLICATION:
Identification of measurable residual disease in AML
PURPOSE OF PROGRAMME:
To assess a laboratory's ability to measurable residual disease using flow cytometry.
ANALYTES:
Analyte | Default Unit |
---|---|
the programme covers a range of leukaemia antigens specific to aml | Percentage size of measurable residual disease population |
MATERIAL PROVIDED: Stabilised leukaemic blood diluted in stabilised whole blood
DISTRIBUTIONS PER YEAR: 4
SAMPLES PER DISTRIBUTION: 3
FREQUENCY OF DISTRIBUTION: 3 monthly as per Trial Schedule (Please note – The Trial Schedule is a guide only and is subject to change)
PROGRAMME OF ANALYSIS:
Results are entered online via the UK NEQAS LI website. Trials are live for 3 weeks. Results can be entered at any time during this period. Under exceptional circumstances late results are accepted at our discretion via email/fax.
DATA ANALYSIS:
Quantitative analysis based on the percentage measurable residual disease.
PERFORMANCE SCORING:
z scores using robust means and robust SDs with standard limits of +2.5 and +3.5 and -2.5 and -3.5 as per ISO 13528 A result between 2.5 and -2.5 would be classed as satisfactory. A result between >2.5 and 3.5 or <-2.5 and -3.5 is seen as an 'Action' result, which highlights a potential issue to the laboratory. Two 'Action' results in a period of 3 samples would result in classification as a 'Critical'. A result above 3.5 or below -3.5 is considered to be a 'Critical' result requiring immediate investigation. Please note that this programme is not currently performance monitored and that these values are provided as information only.
PERFORMANCE MONITORING:
Participant performance is not monitored at this time
PERSISTENT POOR PERFORMANCE:
Participant performance is not monitored at this time
Leucocyte Immunophenotyping
LEUCOCYTE IMMUNOPHENOTYPING The External Quality Assessment Scheme for Leucocyte Immunophenotyping was established by Professor David Barnett in 1986 at Northern General Hospital, Sheffield. In 1990 the Service became known as the UK National External Quality Assessment Service for Leucocyte Immunophenotyping. UK NEQAS LI is part of the Sheffield Teaching Hospitals NHS Foundation Trust. The centre currently provides flow cytometry and molecular haematology based programmes. For the most up-to-date scheme information (including any pilot schemes) please contact the centre directly.
Contact Details
- 4th Floor Pegasus House
- 463a Glossop Road
- Sheffield
- S10 2QD
Leucocyte Immunophenotyping
- Telephone: +44 (0) 114 267 3600
- Fax: +44 (0) 114 267 3601
- Email: admin@ukneqasli.co.uk
- Web: http://www.ukneqasli.co.uk/